"India's Dr Reddy's plans to launch generic obesity drugs in 87 countries next year, CEO says"
doi: Collins, L
The safety profile of pediatric patients treated with empagliflozin was similar to that observed in adults with type 2 diabetes mellitus, with the exception of hypoglycemia risk which was higher in pediatric patients treated with empagliflozin regardless of concomitant insulin use [see WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS ]
[DOI] [PMC free article] [PubMed] [Google Scholar] [79].Chatterjee S, Bandyopadhyay D, Ghosh RK, Majumdar U, Aneja A, Lavie CJ, Deedwania P, Current Problems in Cardiology 2019, 44, 207
This is not a direct comparison since populations differ, but it underscores that PT-141 might not replace PDE5is as the first choice for everyone